Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Dimethyl sulfoxide (DMSO) is a compound used in many products, such as makeup, paint removers, cleaners, essential oils, and as a flavoring agent for certain foods. The compound is also naturally ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

The Merck Future Insight prize was established on the occasion of Merck’s 350th anniversary in 2018 to honour and enable pioneering scientists who are striving to solve some of the biggest ...

Merck lowered 2024 EPS guidance down to $7.94 to $8.03, from its previous guidance of $8.53 to $8.65. The new guidance reflects the negative impact of a one-time charge of $1.3 billion or 51 cents ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

Merck, as a leading science and technology company, operates across healthcare, life sciences and performance materials. From advancing gene editing technologies and discovering unique ways to ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease.

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and ...

Summit Therapeutics (NASDAQ:SMMT) shares soar 51% after its investigational bispecific antibody, ivonescimab, reduced the risk of disease progression or death by 49% compared to Merck’s (NYSE ...